FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 700 publications
Breast Cancer: KOL Insight [2018] US$ 8,495.00 May, 2018
COPD: KOL Insight US$ 8,495.00 Apr, 2018
Ovarian Cancer: KOL Insight US$ 8,495.00 Apr, 2018
Medical Affairs in Emerging Markets US$ 2,495.00 Apr, 2018
Market Access Impact: HIV (EU5) 2018 US$ 5,345.00 Mar, 2018
Market Access Impact: HIV (US) 2018 US$ 5,345.00 Mar, 2018
NPS+ HIV (EU5) 2018 US$ 2,655.00 Feb, 2018
Breast Cancer: Update Bulletin #3 US$ 1,095.00 Feb, 2018
NPS+ Haemophilia B (US) 2018 US$ 2,655.00 Feb, 2018
NPS+ Renal Cell Carcinoma (EU5) 2018 US$ 2,655.00 Feb, 2018
Acute Myeloid Leukaemia:KOL Insight US$ 8,495.00 Feb, 2018
Malignant Melanoma: Update Bulletin US$ 1,095.00 Feb, 2018
NPS+ Haemophilia B (EU5) 2018 US$ 2,655.00 Feb, 2018
1 2 3 4 5 ... 14
Skip to top

Analytics & News by FirstWord